
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is poised for success with a positive regulatory outlook for their pioneering OST-HER2 and OST-tADC drug technologies in the treatment of osteosarcoma and other solid tumors, supported by their recent regulatory designations and potential for accelerated approval pathways. With peak sales projections over $300M and strong potential for non-dilutive funding through Priority Review Voucher qualification, the company is well-positioned for commercial success. However, there are still risks to consider, such as clinical and regulatory risks, partnership and financial risks, and market share risk, which could impact their future prospects. Overall, the company presents a promising opportunity for investors in the biopharmaceutical sector.
Bears say
OS Therapies is facing significant risk factors, including clinical/regulatory, partnership, financial, commercial, legal and intellectual property, and market share risks. Their pipeline of product candidates, while promising, is still in preclinical development and has no revenue generation to support the company's operations. Additionally, with a minimal addressable market in the U.S. of only 108,758-190,899 HER II positive breast cancer patients, there may not be enough demand to drive profitability.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares